See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Social Media
WWE
Donald Trump
Motorsports
Artificial Intelligence
Natural Disasters
Trade War
South America
US Politics
Soccer
Cricket
Published • loading... • Updated

KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a ...

Summary by Hastings Tribune
LEXINGTON, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-004EX, a novel CRISPR-engineered Tumor Infiltrating…

1 Articles

All
Left
Center
1
Right
Hastings TribuneHastings Tribune
Center

KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a ...

LEXINGTON, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-004EX, a novel CRISPR-engineered Tumor Infiltrating…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Wednesday, April 9, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Lexington, Massachusetts

Lexington, Massachusetts

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal